INIS
hyaluronidase
100%
proteins
45%
mice
44%
inflammation
44%
drugs
39%
humans
38%
kidneys
38%
diseases
32%
injuries
32%
density
29%
hyaluronic acid
29%
lysosomes
28%
matrices
24%
epidermis
23%
levels
23%
plasma
23%
clinical trials
21%
tissues
20%
patients
20%
membranes
19%
osteoporosis
18%
messenger-rna
18%
molecular weight
17%
ischemia
16%
permeability
16%
data
16%
size
16%
risks
15%
medicines
14%
genes
14%
balances
14%
death
14%
cancer
14%
barriers
13%
market
13%
production
13%
liver
13%
dermatitis
13%
environment
12%
metabolism
12%
skin
12%
hydrolases
12%
precursor
12%
guidelines
12%
bone mineral density
12%
surfaces
12%
rats
12%
residences
12%
enzymes
11%
macrophages
10%
Keyphrases
Market Access
10%
Risk Data
10%
Early Markets
10%
Access to New Drugs
10%
Risk-benefit
10%
Unilateral Nephrectomy
10%
20-hydroxyeicosatetraenoic Acid (20-HETE)
10%
Sarcopenia
10%
Oncology Care
10%
Cancer Care
10%
Abdominal Sepsis
10%
Fluid Resuscitation
10%
International Approach
10%
Hyaluronan Synthase 3
10%
Hyaluronan Synthase 1
10%
Hyaluronan Metabolism
10%
Drug Information
10%
Pharmacogenomics
10%
Information Associations
10%
Renal Ischemia-reperfusion Injury
10%
Therapeutic Proteins
10%
Biosimilar
10%
Regulatory Requirements
10%
Osteoporosis Treatment
10%
Endothelial Glycocalyx
10%
Subcellular Trafficking
10%
Streptozotocin-induced Diabetes
10%
Postmenopausal Women
10%
Health Technology Assessment
10%
Dosing Recommendations
10%
Angiotensin II (Ang II)
10%
Renal Vascular Reactivity
10%
Naked Mole-rat
10%
Disease Foci
10%
Rat Plasma
10%
Diabetic Vascular Complications
10%
Angiotensin II Type 1 Receptor (AT1R)
10%
Differential Regulation
10%
Renal Injury
10%
Hypertrophy
10%
Cardiopulmonary Dysfunction
10%
MRNA Vaccine
10%
Hyaluronidase 2
10%
PROSPER
10%
GPI-anchored Protein (GPI-AP)
10%
Megakaryocytes
10%
Patient-Reported Outcomes Measurement Information System (PROMIS)
10%
Thrombopoiesis
10%
Patient-reported Outcomes
10%
Safety Event Reporting
10%
